semaglutide weight loss phase 3 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, trial Semaglutide as a GLP-1 Agonist:

Before committing to a multi-month plan, it would be beneficial to clarify these points

Overeating on Wegovy often causes more discomfort than usual due to slower digestion

FDA-approved uses Wegovy is FDA-approved for chronic weight management in patients with obesity (body mass index 30 kg/m or greater) and overweight (body mass index 27 kg/m or greater) with at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, high cholesterol levels, and heart disease, when used as an adjunct to a healthy lifestyle, reduced-calorie diet, and exercise

After years of success and fascination overseas, Wegovy became available to New Zealanders last month

Studies have shown that you can lose anywhere from 12-15% of your total body weight in a 68 week period

January 1, 2025 Update: Judge Marston has issued a scheduling order in the Wegovy and GLP-1 drug litigation, addressing the manufacturers filing of motions to dismiss claims based on arguments that federal preemption shields them from failure-to-warn claims